Skip to main content
Clinical Trials/NCT03588754
NCT03588754
Active, not recruiting
Phase 2

Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking?

Yale University1 site in 1 country20 target enrollmentSeptember 15, 2018

Overview

Phase
Phase 2
Intervention
Propranolol
Conditions
Alcohol Drinking
Sponsor
Yale University
Enrollment
20
Locations
1
Primary Endpoint
Alcohol consumption
Status
Active, not recruiting
Last Updated
8 months ago

Overview

Brief Summary

For this protocol, the investigators plan to conduct a pilot study evaluating the effect of propranolol on alcohol consumption. Using a parallel design, the investigators plan to randomize 20 non-treatment seeking adults with alcohol use disorders (DSM-5) to propranolol extended release (160mg/day or placebo; n=10 per cell) to evaluate whether propranolol reduces alcohol self-administered in the laboratory. Importantly, the investigators will evaluate whether propranolol counteracts stress-induced effects on alcohol self-administration. Following titration to steady state medication levels over a 2-week period, each subject will complete two laboratory sessions consisting of a well validated method for inducing stress or neutral/relaxing state (order counterbalanced), followed by a 2-hour alcohol self-administration paradigm known to be sensitive to medication effects.

Registry
clinicaltrials.gov
Start Date
September 15, 2018
End Date
February 28, 2026
Last Updated
8 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Able to read and write English
  • Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for current (past 6 months) alcohol use disorders
  • Able to take oral medications and willing to adhere to medication regimen

Exclusion Criteria

  • Participants with any significant current medical conditions.
  • Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives \[oral, implant, injection, patch, or ring\], contraceptive sponge, double barrier \[diaphragm or condom plus spermicide\], or IUD)
  • Suicidal, homicidal or evidence of current (past 6-month) mental illness.
  • Specific exclusions for administration of propranolol not already specified.
  • Subjects likely to exhibit clinically significant alcohol withdrawal during the study.

Arms & Interventions

Propranolol

Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.

Intervention: Propranolol

Placebo

Administered orally once daily at 10:00PM

Intervention: Placebo

Outcomes

Primary Outcomes

Alcohol consumption

Time Frame: 120 minutes

Mean mls of alcohol consumed (maximum of 120 mg/dL) for propranolol and placebo groups during 120 minute alcohol self administration sessions taking place as close to Day 15 and Day 19 as possible of medication dosing.

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Propranolol for the Treatment of Acute Stress DisorderStress Disorders, Traumatic, Acute
NCT00069355National Institute of Mental Health (NIMH)50
Completed
Early Phase 1
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube CancerFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal Serous AdenocarcinomaStage II Fallopian Tube Cancer AJCC v6 and v7Stage II Ovarian Cancer AJCC v6 and v7Stage IIA Fallopian Tube Cancer AJCC v6 and v7Stage IIA Ovarian Cancer AJCC V6 and v7Stage IIB Fallopian Tube Cancer AJCC v6 and v7Stage IIB Ovarian Cancer AJCC v6 and v7Stage IIC Fallopian Tube Cancer AJCC v6 and v7Stage IIC Ovarian Cancer AJCC v6 and v7Stage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7
NCT01504126M.D. Anderson Cancer Center32
Completed
Phase 2
Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT RecipientsMultiple Myeloma
NCT02420223Medical College of Wisconsin25
Unknown
Not Applicable
Effect of Propranolol on the Autonomic Nervous System and Muscle PainTemporomandibular Joint DisordersMyofascial Temporomandibular Disorders
NCT01333150University of Aarhus16
Completed
Phase 3
Beta-Blocker Heart Attack Trial (BHAT)ArrhythmiaCardiovascular DiseasesCoronary DiseaseDeath, Sudden, CardiacHeart DiseasesMyocardial InfarctionMyocardial IschemiaVentricular Fibrillation
NCT00000492National Heart, Lung, and Blood Institute (NHLBI)